mAbxience and MS Pharma Sign Partnership for Denosumab Biosimilar in Select MEA CountriesMiguel Martínez-Cava2023-11-13T07:53:41+01:00November 13, 2023|Read More
mAbxience and Amneal Strengthen Alliance with Two Denosumab Biosimilars in the U.S. for the Treatment of Oncology and Bone DiseasesClara Prieto2023-10-21T14:44:19+02:00October 12, 2023|Read More
mAbxience and Abbott Sign Strategic Agreement to Broaden Access to a Pipeline of Biosimilars in Key Emerging MarketsMiguel Martínez-Cava2023-10-05T16:05:09+02:00September 20, 2023|Read More
